炎症性肠病并发常见机会性病毒感染患者的临床特点及处理策略

doi:10.12114/j.issn.1007-9572.2021.00.407

摘要/Abstract

摘要： 炎症性肠病（IBD）是一种慢性炎症性肠道疾病，主要包括溃疡性结肠炎（UC）和克罗恩病（CD）。目前，虽然IBD的发病机制尚未完全明确，但已明确其是一种在胃肠道表现出异常免疫反应的自身免疫性疾病，因此包括激素、免疫抑制剂及生物制剂在内的药物治疗已成为IBD的主要治疗方式。免疫抑制剂等主要通过有针对性地干预免疫反应的不同阶段而达到治疗效果，但由于IBD患者营养状况、免疫功能较差及相关药物对免疫功能的抑制，其抵御病原体侵袭的能力被削弱，机会性感染风险明显升高。本文主要分析了IBD并发常见机会性病毒感染患者的临床特点及处理策略，以期为临床有效管理此类患者提供参考。

关键词: 炎性肠疾病；结肠炎, 溃疡性；Crohn病；机会致病菌感染；机会性病毒感染；病毒性疾病；综述

Abstract: Inflammatory bowel disease（IBD）is a term used to describe ulcerative colitis and Crohn's disease，manifested by chronic inflammation of the gastrointestinal tract.Although its pathogenesis remains unclear，it has been recognized as an autoimmune disease with abnormal immune response in the gastrointestinal tract.Current treatments mainly include drug therapies such as steroid，immune inhibitors and biological agents，and their effects mainly attribute to targeted intervention in different stages of immune response in the process of IBD.As the body's defense against pathogens is impaired due to declined nutritional and immune status as well as application of immunomodulatory，patients with IBD have a significant increase in the risk of opportunistic infection.This paper mainly reviewed the clinical features and management strategies of opportunistic viral infections in patients with IBD，hoping to provide a reference for clinical efficient management.

Key words: Inflammatory bowel diseases；Colitis, ulcerative；Crohn disease；Opportunistic infections；Opportunistic viral infection；Virus diseases；Review

吴榕,王英德,毛靖伟. 炎症性肠病并发常见机会性病毒感染患者的临床特点及处理策略[J]. 中国全科医学, 2021, 24(15): 1853-1860. DOI: 10.12114/j.issn.1007-9572.2021.00.407.
WU Rong,WANG Yingde,MAO Jingwei. Opportunistic Viral Infections in Patients with Inflammatory Bowel Disease：Clinical Features and Management Strategies　[J]. Chinese General Practice, 2021, 24(15): 1853-1860. DOI: 10.12114/j.issn.1007-9572.2021.00.407.

参考文献

［1］SHERIFF M Z，MANSOOR E，LUTHER J，et al．Opportunistic infections are more prevalent in Crohn's disease and ulcerative colitis：a large population-based study［J］．Inflamm Bowel Dis，2020，26（2）：291-300．DOI：10.1093/ibd/izz147.
［2］GONG S S，FAN Y H，HAN Q Q，et al．Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease［J］．World J Gastroenterol，2019，25（18）：2240-2250．DOI：10.3748/wjg.v25.i18.2240.
［3］COHEN R D，BHAYAT F，BLAKE A，et al．The safety profile of vedolizumab in ulcerative colitis and Crohn's disease：4 years of global post-marketing data［J］．J Crohns Colitis，2020，14（2）：192-204．DOI：10.1093/ecco-jcc/jjz137.
［4］KIRCHGESNER J，LEMAITRE M，CARRAT F，et al．Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases［J］．Gastroenterology，2018，155（2）：337-346.e10．DOI：10.1053/j.gastro.2018.04.012.
［5］GREENER T，KABAKCHIEV B，STEINHART A H，et al．Higher infliximab levels are not associated with an increase in adverse events in inflammatory bowel disease［J］．Inflamm Bowel Dis，2018，24（8）：1808-1814．DOI：10.1093/ibd/izy066.
［6］BORMAN Z A，C?Té-DAIGNEAULT J，COLOMBEL J F.The risk for opportunistic infections in inflammatory bowel disease with biologics：an update［J］．Expert Rev Gastroenterol Hepatol，2018，12（11）：1101-1108．DOI：10.1080/17474124.2018.1530983.
［7］NG S C，HILMI I N，BLAKE A，et al．Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting［J］．Inflamm Bowel Dis，2018，24（11）：2431-2441．DOI：10.1093/ibd/izy153.
［8］CHAN W，KARIYAWASAM V C，KIM S，et al．Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis：an international survey［J］．Eur J Gastroenterol Hepatol，2020，32（8）：976-983．DOI：10.1097/MEG.0000000000001768.
［9］Inflammatory Bowel Disease Group，Chinese Society of Gastroenterology，Chinese Medical Association.Evidence-based consensus on opportunistic infections in inflammatory bowel disease（republication）［J］．Intest Res，2018，16（2）：178-193．DOI：10.5217/ir.2018.16.2.178.
［10］HUANG M L，XU X T，SHEN J，et al．Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China：a retrospective study［J］．J Crohns Colitis，2014，8（4）：282-287．DOI：10.1016/j.crohns.2013.08.017.
［11］HARSH P，GUPTA V，KEDIA S，et al．Prevalence of hepatitis B，hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India［J］．Intest Res，2017，15（1）：97-102．DOI：10.5217/ir.2017.15.1.97.
［12］GISBERT J P，CHAPARRO M，ESTEVE M.Review article：prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease［J］．Aliment Pharmacol Ther，2011，33（6）：619-633．DOI：10.1111/j.1365-2036.2010.04570.x.
［13］BELLE A，BAUMANN C，BIGARD M A，et al．Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases［J］．Eur J Gastroenterol Hepatol，2015，27（8）：877-881．DOI：10.1097/MEG.0000000000000370.
［14］CHANG J Y，JUNG S A，MOON C M，et al．Response to hepatitis B vaccination in patients with inflammatory bowel disease：a prospective observational study in Korea［J］．Intest Res，2018，16（4）：599-608．DOI：10.5217/ir.2018.00012.
［15］PRATT P K Jr，DAVID N，WEBER H C，et al．Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy［J］．Inflamm Bowel Dis，2018，24（2）：380-386．DOI：10.1093/ibd/izx001.
［16］PRATT P K Jr，NUNES D，LONG M T，et al．Improved antibody response to three additional hepatitis B vaccine doses following primary vaccination failure in patients with inflammatory bowel disease［J］．Dig Dis Sci，2019，64（7）：2031-2038．DOI：10.1007/s10620-019-05595-6.
［17］LóPEZ-SERRANO P，PéREZ-CALLE J L，SáNCHEZ-TEMBLEQUE M D.Hepatitis B and inflammatory bowel disease：role of antiviral prophylaxis［J］．World J Gastroenterol，2013，19（9）：1342-1348．DOI：10.3748/wjg.v19.i9.1342.
［18］CHEN D，LUO S，BEN Q，et al．Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China［J］．Eur J Gastroenterol Hepatol，2017，29（5）：509-515．DOI：10.1097/MEG.0000000000000838.
［19］DEGASPERI E，CAPRIOLI F，EL SHERIF O，et al．Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection［J］．Expert Rev Gastroenterol Hepatol，2016，10（12）：1373-1383．DOI：10.1080/17474124.2016.1246181.
［20］LIN M V，BLONSKI W，BUCHNER A M，et al．The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease［J］．Dig Dis Sci，2013，58（4）：1149-1156．DOI：10.1007/s10620-012-2457-0.
［21］SEO K I，KANG S B.Hepatobiliary manifestation of inflammatory bowel disease［J］．Korean J Gastroenterol，2019，73（5）：248-259．DOI：10.4166/kjg.2019.73.5.248.
［22］DAVE M，PUROHIT T，RAZONABLE R，et al．Opportunistic infections due to inflammatory bowel disease therapy［J］．Inflamm Bowel Dis，2014，20（1）：196-212．DOI：10.1097/MIB.0b013e3182a827d2.
［23］RAHIER J F，MAGRO F，ABREU C，et al．Second European evidence-based consensus on the prevention，diagnosis and management of opportunistic infections in inflammatory bowel disease［J］．J Crohns Colitis，2014，8（6）：443-468．DOI：10.1016/j.crohns.2013.12.013.
［24］GHARTAVOL Z V，ALAVIAN S M，AMINI S，et al．Prevalence of occult hepatitis B virus in plasma and peripheral blood mononuclear cell compartments of patients with chronic hepatitis C infection in tehran-iran［J］．Hepat Mon，2013，13（5）：e10134．DOI：10.5812/hepatmon.10134.
［25］ALLEN A M，KIM W R，LARSON J，et al．Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease［J］．Clin Gastroenterol Hepatol，2013，11（12）：1655-1660.e1．DOI：10.1016/j.cgh.2013.07.014.
［26］IMPERATORE N，CASTIGLIONE F，RISPO A，et al．Timing strategies of direct-acting antivirals and biologics administration in HCV-infected subjects with inflammatory bowel diseases［J］．Front Pharmacol，2017，8：867．DOI：10.3389/fphar.2017.00867.
［27］MOURAD F H，HASHASH J G，KARIYAWASAM V C，et al．Ulcerative colitis and cytomegalovirus infection：from A to Z［J］．J Crohns Colitis，2020，14（8）：1162-1171．DOI：10.1093/ecco-jcc/jjaa036.
［28］ROWAN C，JUDGE C，CANNON M D，et al．Severe symptomatic primary CMV infection in inflammatory bowel disease patients with low population seroprevalence［J］．Gastroenterol Res Pract，2018，2018：1029401．DOI：10.1155/2018/1029401.
［29］JOHNSON J，AFFOLTER K，BOYNTON K，et al．CMV disease in IBD：comparison of diagnostic tests and correlation with disease outcome［J］．Inflamm Bowel Dis，2018，24（7）：1539-1546．DOI：10.1093/ibd/izy045.
［30］JENTZER A，VEYRARD P，ROBLIN X，et al．Cytomegalovirus and inflammatory bowel diseases（IBD）with a special focus on the link with ulcerative colitis（UC）［J］．Microorganisms，2020，8（7）：1078．DOI：10.3390/microorganisms8071078.
［31］SHUKLA T，SINGH S，TANDON P，et al．Corticosteroids and thiopurines，but not tumor necrosis factor antagonists，are associated with cytomegalovirus reactivation in inflammatory bowel disease：a systematic review and meta-analysis［J］．J Clin Gastroenterol，2017，51（5）：394-401．DOI：10.1097/MCG.0000000000000758.
［32］JUNG K H，KIM J，LEE H S，et al．Clinical implications of the CMV-specific T-cell response and local or systemic CMV viral replication in patients with moderate to severe ulcerative colitis［J］．Open Forum Infect Dis，2019，6（12）：ofz526．DOI：10.1093/ofid/ofz526.
［33］GROSSBERG L B，EZAZ G，GRUNWALD D，et al．A national survey of the prevalence and impact of cytomegalovirus infection among hospitalized patients with ulcerative colitis［J］．J Clin Gastroenterol，2018，52（3）：241-245．DOI：10.1097/MCG.0000000000000736.
［34］PARK S C，JEEN Y M，JEEN Y T.Approach to cytomegalovirus infections in patients with ulcerative colitis［J］．Korean J Intern Med，2017，32（3）：383-392．DOI：10.3904/kjim.2017.087.
［35］WU S，HE C，TANG T Y，et al．A review on co-existent Epstein-Barr virus-induced complications in inflammatory bowel disease［J］．Eur J Gastroenterol Hepatol，2019，31（9）：1085-1091．DOI：10.1097/MEG.0000000000001474.
［36］LI X，CHEN N，YOU P，et al．The status of Epstein-Barr virus infection in intestinal mucosa of Chinese patients with inflammatory bowel disease［J］．Digestion，2019，99（2）：126-132．DOI：10.1159/000489996.
［37］MA M X，PARRY J，VENUGOPAL K，et al．Gastrointestinal：an unusual opportunistic infection mimicking lymphoma in a patient receiving Infliximab for Crohn's disease［J］．J Gastroenterol Hepatol，2017，32（6）：1131．DOI：10.1111/jgh.13615.
［38］HRADSKY O，COPOVA I，ZARUBOVA K，et al．Seroprevalence of Epstein-Barr virus，cytomegalovirus，and polyomaviruses in children with inflammatory bowel disease［J］．Dig Dis Sci，2015，60（11）：3399-3407．DOI：10.1007/s10620-015-3764-z.
［39］LEVHAR N，UNGAR B，KOPYLOV U，et al．Propagation of EBV-driven lymphomatous transformation of peripheral blood B cells by immunomodulators and biologics used in the treatment of inflammatory bowel disease［J］．Inflamm Bowel Dis，2020，26（9）：1330-1339．DOI：10.1093/ibd/izaa065.
［40］NING L，LIU R，LI S，et al．Increased risk of herpes zoster infection in patients with inflammatory bowel disease：a meta-analysis of cohort studies［J］．Eur J Clin Microbiol Infect Dis，2020，39（2）：219-227．DOI：10.1007/s10096-019-03706-9.
［41］WINTHROP K L，MELMED G Y，VERMEIRE S，et al．Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib［J］．Inflamm Bowel Dis，2018，24（10）：2258-2265．DOI：10.1093/ibd/izy131.
［42］KHAN N，TRIVEDI C，KAVANI H，et al．Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases［J］．Clin Gastroenterol Hepatol，2019，17（7）：1341-1347．DOI：10.1016/j.cgh.2018.10.016.
［43］WASAN S K，ZULLOW S，BERG A，et al．Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression［J］．Inflamm Bowel Dis，2016，22（6）：1391-1396．DOI：10.1097/MIB.0000000000000743.
［44］CLICK B，REGUEIRO M.Managing risks with biologics［J］．Curr Gastroenterol Rep，2019，21（2）：1．DOI：10.1007/s11894-019-0669-6.
［45］KHAN N，PATEL D，TRIVEDI C，et al．Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases：a nationwide cohort study［J］．Clin Gastroenterol Hepatol，2018，16（12）：1919-1927.e3．DOI：10.1016/j.cgh.2017.12.052.
［46］ZABANA Y，RODRíGUEZ L，LOBATóN T，et al．Relevant infections in inflammatory bowel disease，and their relationship with immunosuppressive therapy and their effects on disease mortality［J］．J Crohns Colitis，2019，13（7）：828-837．DOI：10.1093/ecco-jcc/jjz013.
［47］KHAN N，TRIVEDI C，SHAH Y，et al．The severity of herpes zoster in inflammatory bowel disease patients treated with anti-TNF agents［J］．Inflamm Bowel Dis，2018，24（6）：1274-1279．DOI：10.1093/ibd/izx115.
［48］SANDBORN W J，PANES J，D'HAENS G R，et al．Safety of tofacitinib for treatment of ulcerative colitis，based on 4.4 years of data from global clinical trials［J］．Clin Gastroenterol Hepatol，2019，17（8）：1541-1550．DOI：10.1016/j.cgh.2018.11.035.
［49］DEEPAK P，ALAYO Q A，KHATIWADA A，et al．Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis［J］．Clin Gastroenterol Hepatol，2020．DOI：10.1016/j.cgh.2020.06.050.
［50］KOSHY E，MENGTING L，KUMAR H，et al．Epidemiology，treatment and prevention of herpes zoster：a comprehensive review［J］．Indian J Dermatol Venereol Leprol，2018，84（3）：251-262．DOI：10.4103/ijdvl.IJDVL_1021_16.
［51］DAREHRANJ S M，ALATAB S，VAHEDI H，et al．Efficacy of anti-TNF therapy for the treatment of patients with moderate-to-severe inflammatory bowel disease；a first Iranian report［J］．Middle East J Dig Dis，2020，12（1）：12-18．DOI：10.15171/mejdd.2020.158.